The latest announcement is out from Aquestive Therapeutics ( (AQST) ).
Aquestive Therapeutics announced promising results from their Oral Allergy Syndrome (OAS) study for Anaphylm™, a sublingual epinephrine film. This innovative treatment, if approved by the FDA, could become the first non-invasive oral option for severe allergic reactions, offering rapid symptom relief within minutes. The study met all endpoints, demonstrating Anaphylm’s consistent pharmacokinetic profile, safety, and effectiveness, paving the way for a potential NDA submission and a groundbreaking entry into the allergy treatment market.
Find detailed analytics on AQST stock on TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
